ES2336286T3 - Ensayos aglutrimetricos en sangre. - Google Patents
Ensayos aglutrimetricos en sangre. Download PDFInfo
- Publication number
- ES2336286T3 ES2336286T3 ES98913184T ES98913184T ES2336286T3 ES 2336286 T3 ES2336286 T3 ES 2336286T3 ES 98913184 T ES98913184 T ES 98913184T ES 98913184 T ES98913184 T ES 98913184T ES 2336286 T3 ES2336286 T3 ES 2336286T3
- Authority
- ES
- Spain
- Prior art keywords
- particles
- infrared
- sample
- aggregation
- light
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 75
- 239000008280 blood Substances 0.000 title claims abstract description 75
- 238000012360 testing method Methods 0.000 title claims description 61
- 239000002245 particle Substances 0.000 claims abstract description 154
- 238000000034 method Methods 0.000 claims abstract description 62
- 229940012952 fibrinogen Drugs 0.000 claims abstract description 39
- 108010049003 Fibrinogen Proteins 0.000 claims abstract description 37
- 102000008946 Fibrinogen Human genes 0.000 claims abstract description 37
- 230000027455 binding Effects 0.000 claims abstract description 35
- 230000008859 change Effects 0.000 claims abstract description 16
- 230000031700 light absorption Effects 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 71
- 239000000203 mixture Substances 0.000 claims description 58
- 230000002776 aggregation Effects 0.000 claims description 54
- 238000004220 aggregation Methods 0.000 claims description 54
- 239000003153 chemical reaction reagent Substances 0.000 claims description 39
- 238000010521 absorption reaction Methods 0.000 claims description 36
- -1 4-Dimethylaminophenyl Chemical group 0.000 claims description 29
- 108090000190 Thrombin Proteins 0.000 claims description 21
- 229960004072 thrombin Drugs 0.000 claims description 21
- 239000003112 inhibitor Substances 0.000 claims description 20
- 230000000694 effects Effects 0.000 claims description 19
- 230000005540 biological transmission Effects 0.000 claims description 17
- 102000004169 proteins and genes Human genes 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 claims description 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 13
- 239000003146 anticoagulant agent Substances 0.000 claims description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 10
- 229940127219 anticoagulant drug Drugs 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims description 8
- 238000004132 cross linking Methods 0.000 claims description 8
- 239000003446 ligand Substances 0.000 claims description 8
- UVLDECUUBLLYRG-UHFFFAOYSA-M n-[(5e)-2-[2-(5-chloro-3-ethyl-1,3-benzothiazol-3-ium-2-yl)ethenyl]-5-[(2z)-2-(5-chloro-3-ethyl-1,3-benzothiazol-2-ylidene)ethylidene]cyclopenten-1-yl]-n-phenylaniline;perchlorate Chemical compound [O-]Cl(=O)(=O)=O.S1C2=CC=C(Cl)C=C2N(CC)C1=CC=C1CCC(C=CC2=[N+](C3=CC(Cl)=CC=C3S2)CC)=C1N(C=1C=CC=CC=1)C1=CC=CC=C1 UVLDECUUBLLYRG-UHFFFAOYSA-M 0.000 claims description 8
- 239000012190 activator Substances 0.000 claims description 7
- 238000010790 dilution Methods 0.000 claims description 7
- 239000012895 dilution Substances 0.000 claims description 7
- 108010017446 glycyl-prolyl-arginyl-proline Proteins 0.000 claims description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical group [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 6
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical group CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 6
- 108010038807 Oligopeptides Proteins 0.000 claims description 6
- 102000015636 Oligopeptides Human genes 0.000 claims description 6
- WXPZDDCNKXMOMC-AVGNSLFASA-N (2s)-1-[(2s)-2-[[(2s)-1-(2-aminoacetyl)pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carboxylic acid Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@H](C(O)=O)CCC1 WXPZDDCNKXMOMC-AVGNSLFASA-N 0.000 claims description 5
- 102000008186 Collagen Human genes 0.000 claims description 5
- 108010035532 Collagen Proteins 0.000 claims description 5
- 229920001436 collagen Polymers 0.000 claims description 5
- 239000002250 absorbent Substances 0.000 claims description 4
- 230000002745 absorbent Effects 0.000 claims description 4
- 239000000853 adhesive Substances 0.000 claims description 4
- 230000001070 adhesive effect Effects 0.000 claims description 4
- 239000005312 bioglass Substances 0.000 claims description 4
- 239000003054 catalyst Substances 0.000 claims description 4
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 4
- 229920000620 organic polymer Polymers 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 230000009471 action Effects 0.000 claims description 3
- 230000015271 coagulation Effects 0.000 claims description 3
- 238000005345 coagulation Methods 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 239000006096 absorbing agent Substances 0.000 claims description 2
- 210000000170 cell membrane Anatomy 0.000 claims description 2
- UOQZCYHZXQOTPV-UHFFFAOYSA-M diethyl-[4-[1,5,5-tris[4-(diethylamino)phenyl]penta-2,4-dienylidene]cyclohexa-2,5-dien-1-ylidene]azanium;perchlorate Chemical compound [O-]Cl(=O)(=O)=O.C1=CC(N(CC)CC)=CC=C1C(C=1C=CC(=CC=1)N(CC)CC)=C\C=C\C(C=1C=CC(=CC=1)N(CC)CC)=C1C=CC(=[N+](CC)CC)C=C1 UOQZCYHZXQOTPV-UHFFFAOYSA-M 0.000 claims description 2
- 230000002163 immunogen Effects 0.000 claims description 2
- 230000003278 mimic effect Effects 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 6
- 230000001678 irradiating effect Effects 0.000 claims 6
- MLENNECRNUHQQS-UHFFFAOYSA-N (4z)-1-ethyl-4-[(2e,4e)-5-(1-ethylquinolin-1-ium-4-yl)penta-2,4-dienylidene]quinoline Chemical compound C12=CC=CC=C2N(CC)C=CC1=CC=CC=CC1=CC=[N+](CC)C2=CC=CC=C12 MLENNECRNUHQQS-UHFFFAOYSA-N 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 239000003060 catalysis inhibitor Substances 0.000 claims 3
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 claims 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims 3
- SMWDFEZZVXVKRB-UHFFFAOYSA-O hydron;quinoline Chemical compound [NH+]1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-O 0.000 claims 3
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 3
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims 3
- DZVCFNFOPIZQKX-LTHRDKTGSA-M merocyanine Chemical compound [Na+].O=C1N(CCCC)C(=O)N(CCCC)C(=O)C1=C\C=C\C=C/1N(CCCS([O-])(=O)=O)C2=CC=CC=C2O\1 DZVCFNFOPIZQKX-LTHRDKTGSA-M 0.000 claims 3
- 239000000758 substrate Substances 0.000 claims 3
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 claims 3
- 125000005287 vanadyl group Chemical group 0.000 claims 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 3
- 229920002554 vinyl polymer Polymers 0.000 claims 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 2
- 239000007983 Tris buffer Substances 0.000 claims 2
- 230000003197 catalytic effect Effects 0.000 claims 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 claims 2
- 239000000470 constituent Substances 0.000 claims 1
- 230000004520 agglutination Effects 0.000 abstract description 13
- 239000000523 sample Substances 0.000 description 83
- 239000000306 component Substances 0.000 description 39
- 239000000975 dye Substances 0.000 description 35
- 239000004816 latex Substances 0.000 description 19
- 229920000126 latex Polymers 0.000 description 19
- 239000011324 bead Substances 0.000 description 17
- 230000006870 function Effects 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 14
- 102000005962 receptors Human genes 0.000 description 13
- 108020003175 receptors Proteins 0.000 description 13
- 239000000872 buffer Substances 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 10
- 230000003993 interaction Effects 0.000 description 9
- 210000002381 plasma Anatomy 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 239000004793 Polystyrene Substances 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 230000003287 optical effect Effects 0.000 description 8
- 229920002223 polystyrene Polymers 0.000 description 8
- 238000005259 measurement Methods 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- 238000006213 oxygenation reaction Methods 0.000 description 7
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 6
- 239000004743 Polypropylene Substances 0.000 description 6
- 238000013019 agitation Methods 0.000 description 6
- 229920001155 polypropylene Polymers 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
- 102000009123 Fibrin Human genes 0.000 description 5
- 108010073385 Fibrin Proteins 0.000 description 5
- 239000007995 HEPES buffer Substances 0.000 description 5
- 108010035030 Platelet Membrane Glycoprotein IIb Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 229950003499 fibrin Drugs 0.000 description 5
- 229940106780 human fibrinogen Drugs 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 108010054147 Hemoglobins Proteins 0.000 description 4
- 102000001554 Hemoglobins Human genes 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 230000009870 specific binding Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000003868 thrombin inhibitor Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 229940122388 Thrombin inhibitor Drugs 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000002523 gelfiltration Methods 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000011859 microparticle Substances 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 108010048623 Collagen Receptors Proteins 0.000 description 2
- 241000557626 Corvus corax Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102100025305 Integrin alpha-2 Human genes 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 108010035766 P-Selectin Proteins 0.000 description 2
- 102100023472 P-selectin Human genes 0.000 description 2
- 108010022425 Platelet Glycoprotein GPIIb-IIIa Complex Proteins 0.000 description 2
- 102000015795 Platelet Membrane Glycoproteins Human genes 0.000 description 2
- 108010010336 Platelet Membrane Glycoproteins Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 description 2
- 101710090322 Truncated surface protein Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 2
- 238000000149 argon plasma sintering Methods 0.000 description 2
- 235000019606 astringent taste Nutrition 0.000 description 2
- 235000013405 beer Nutrition 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 239000003130 blood coagulation factor inhibitor Substances 0.000 description 2
- 239000012503 blood component Substances 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- LKKPNUDVOYAOBB-UHFFFAOYSA-N naphthalocyanine Chemical compound N1C(N=C2C3=CC4=CC=CC=C4C=C3C(N=C3C4=CC5=CC=CC=C5C=C4C(=N4)N3)=N2)=C(C=C2C(C=CC=C2)=C2)C2=C1N=C1C2=CC3=CC=CC=C3C=C2C4=N1 LKKPNUDVOYAOBB-UHFFFAOYSA-N 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 239000000816 peptidomimetic Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004032 porphyrins Chemical class 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 230000002537 thrombolytic effect Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- NALBXTAOVMLCIX-UHFFFAOYSA-M (2e)-2-[(2e)-2-[2-chloro-3-[(e)-2-(1,3,3-trimethylindol-1-ium-2-yl)ethenyl]cyclohex-2-en-1-ylidene]ethylidene]-1,3,3-trimethylindole;perchlorate Chemical compound [O-]Cl(=O)(=O)=O.CC1(C)C2=CC=CC=C2N(C)C1=CC=C1C(Cl)=C(C=CC=2C(C3=CC=CC=C3[N+]=2C)(C)C)CCC1 NALBXTAOVMLCIX-UHFFFAOYSA-M 0.000 description 1
- QISHCOOKKXNXNW-UHFFFAOYSA-M 1-ethyl-2-[7-(1-ethylquinolin-1-ium-2-yl)hepta-2,4,6-trienylidene]quinoline;iodide Chemical compound [I-].C1=CC2=CC=CC=C2N(CC)\C1=C\C=C\C=C\C=C\C1=CC=C(C=CC=C2)C2=[N+]1CC QISHCOOKKXNXNW-UHFFFAOYSA-M 0.000 description 1
- XDGZLJIBGBJNTI-UHFFFAOYSA-M 1-ethyl-4-[5-(1-ethylquinolin-1-ium-4-yl)penta-2,4-dienylidene]quinoline;iodide Chemical compound [I-].C12=CC=CC=C2N(CC)C=C\C1=C/C=C/C=C/C1=CC=[N+](CC)C2=CC=CC=C12 XDGZLJIBGBJNTI-UHFFFAOYSA-M 0.000 description 1
- CRFQJHNXTNBRQR-ZDUSSCGKSA-N 2-[(3s)-4-[2-[(4-carbamimidoylbenzoyl)amino]acetyl]-3-(2-methoxy-2-oxoethyl)-2-oxopiperazin-1-yl]acetic acid Chemical compound C1CN(CC(O)=O)C(=O)[C@H](CC(=O)OC)N1C(=O)CNC(=O)C1=CC=C(C(N)=N)C=C1 CRFQJHNXTNBRQR-ZDUSSCGKSA-N 0.000 description 1
- VFXZKNGPBLVKPC-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid;sodium Chemical group [Na].OCCN1CCN(CCS(O)(=O)=O)CC1 VFXZKNGPBLVKPC-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- 108010069112 Complement System Proteins Proteins 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 1
- 229940123900 Direct thrombin inhibitor Drugs 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 108010056764 Eptifibatide Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108010014172 Factor V Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 229940124138 GP antagonist Drugs 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 101000621371 Homo sapiens WD and tetratricopeptide repeats protein 1 Proteins 0.000 description 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
- 101000892274 Human adenovirus C serotype 2 Adenovirus death protein Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010092694 L-Selectin Proteins 0.000 description 1
- 102100033467 L-selectin Human genes 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108010064719 Oxyhemoglobins Proteins 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 102100038124 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 101000820656 Rattus norvegicus Seminal vesicle secretory protein 4 Proteins 0.000 description 1
- 108010081391 Ristocetin Proteins 0.000 description 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 102100036859 Troponin I, cardiac muscle Human genes 0.000 description 1
- 101710128251 Troponin I, cardiac muscle Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- IBVMKPUIRNJREW-UHFFFAOYSA-N [I-].[NH2+]1CC=CC2=CC=CC=C12 Chemical compound [I-].[NH2+]1CC=CC2=CC=CC=C12 IBVMKPUIRNJREW-UHFFFAOYSA-N 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004523 agglutinating effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 230000003302 anti-idiotype Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- KXNPVXPOPUZYGB-XYVMCAHJSA-N argatroban Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2 KXNPVXPOPUZYGB-XYVMCAHJSA-N 0.000 description 1
- 229960003856 argatroban Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 108010055460 bivalirudin Proteins 0.000 description 1
- 229960001500 bivalirudin Drugs 0.000 description 1
- OIRCOABEOLEUMC-GEJPAHFPSA-N bivalirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OIRCOABEOLEUMC-GEJPAHFPSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229960000182 blood factors Drugs 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- BGTFCAQCKWKTRL-YDEUACAXSA-N chembl1095986 Chemical compound C1[C@@H](N)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]([C@H]1C(N[C@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(C(=C(O)C=4)C)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@@H](C(=O)N3)[C@H](O)C=3C=CC(O4)=CC=3)C(=O)N1)C(O)=O)=O)C(C=C1)=CC=C1OC1=C(O[C@@H]3[C@H]([C@H](O)[C@@H](O)[C@H](CO[C@@H]5[C@H]([C@@H](O)[C@H](O)[C@@H](C)O5)O)O3)O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3[C@H]([C@H](O)[C@@H](CO)O3)O)C4=CC2=C1 BGTFCAQCKWKTRL-YDEUACAXSA-N 0.000 description 1
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 1
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 1
- KQNKHCQMQRDLKZ-UHFFFAOYSA-M disodium dihydrogen phosphate azide Chemical compound P(=O)([O-])(O)O.[Na+].[N-]=[N+]=[N-].[Na+] KQNKHCQMQRDLKZ-UHFFFAOYSA-M 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960004242 dronabinol Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000002158 endotoxin Chemical class 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- CZKPOZZJODAYPZ-LROMGURASA-N eptifibatide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCCNC(=N)N)NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]1CC1=CNC2=CC=CC=C12 CZKPOZZJODAYPZ-LROMGURASA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 108010064044 fibronectinase Proteins 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 229940125672 glycoprotein IIb/IIIa inhibitor Drugs 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001965 increasing effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940056984 integrilin Drugs 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229920006008 lipopolysaccharide Chemical class 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000003055 low molecular weight heparin Substances 0.000 description 1
- 229940127215 low-molecular weight heparin Drugs 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229910052755 nonmetal Inorganic materials 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 108010011903 peptide receptors Proteins 0.000 description 1
- 102000014187 peptide receptors Human genes 0.000 description 1
- 229930192851 perforin Natural products 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical compound N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 210000004623 platelet-rich plasma Anatomy 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 239000002461 renin inhibitor Substances 0.000 description 1
- 229940086526 renin-inhibitors Drugs 0.000 description 1
- 229940107685 reopro Drugs 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 229950004257 ristocetin Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000012475 sodium chloride buffer Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229920005613 synthetic organic polymer Polymers 0.000 description 1
- 229960003766 thrombin (human) Drugs 0.000 description 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
- 229960005001 ticlopidine Drugs 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 108010078608 transamidases Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 108010047303 von Willebrand Factor Proteins 0.000 description 1
- 102100036537 von Willebrand factor Human genes 0.000 description 1
- 229960001134 von willebrand factor Drugs 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54346—Nanoparticles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Nanotechnology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US820999 | 1997-03-20 | ||
| US08/820,999 US5922551A (en) | 1997-03-20 | 1997-03-20 | Agglutrimetric platelet binding assays in blood |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2336286T3 true ES2336286T3 (es) | 2010-04-09 |
Family
ID=25232240
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES98913184T Expired - Lifetime ES2336286T3 (es) | 1997-03-20 | 1998-03-20 | Ensayos aglutrimetricos en sangre. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US5922551A (https=) |
| EP (1) | EP1012604B1 (https=) |
| JP (1) | JP3881036B2 (https=) |
| AT (1) | ATE452341T1 (https=) |
| AU (1) | AU6779698A (https=) |
| CA (1) | CA2284559C (https=) |
| DE (1) | DE69841387D1 (https=) |
| ES (1) | ES2336286T3 (https=) |
| WO (1) | WO1998041868A1 (https=) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6432715B1 (en) * | 1998-02-24 | 2002-08-13 | Isotag Technology, Inc. | Method for marking items for identification |
| WO2000025140A1 (en) * | 1998-10-23 | 2000-05-04 | Accumetrics, Inc. | Method for determining platelet count |
| WO2000029831A1 (en) * | 1998-11-13 | 2000-05-25 | Bangs Laboratories, Inc. | Labeling microparticles capable of absorbing infrared light and methods of making and using the same |
| AU5044400A (en) * | 1999-05-28 | 2000-12-18 | Sendx Medical, Inc. | Control for methods for determining platelet count and platelet function |
| US6316264B1 (en) * | 1999-12-17 | 2001-11-13 | Bayer Corporation | Test strip for the assay of an analyte in a liquid sample |
| DE10013377A1 (de) * | 2000-03-17 | 2001-09-20 | Dade Behring Marburg Gmbh | Induzierte Aggregation und Agglutination von Plättchen |
| AU2001261020A1 (en) * | 2000-05-09 | 2001-11-20 | Pharmanetics Incorporated | Platelet function assay and reagent therefor |
| GB0015923D0 (en) * | 2000-06-30 | 2000-08-23 | Astrazeneca Ab | Methods |
| DE10038900A1 (de) * | 2000-08-09 | 2002-03-07 | Haemosys Gmbh | Einfache Methode zum drug monitoring von GPIIb/IIIa-Rezeptor-Antagonisten |
| WO2002016506A2 (en) * | 2000-08-24 | 2002-02-28 | Sendx Medical, Inc. | The use of a multiple dye system to enhance the spectral properties of dyed microparticles in an immunoassay |
| US6689615B1 (en) | 2000-10-04 | 2004-02-10 | James Murto | Methods and devices for processing blood samples |
| JP2004069677A (ja) * | 2002-06-13 | 2004-03-04 | Canon Inc | 免疫学的測定方法、免疫学的測定用試薬及びその製造方法 |
| US7655411B2 (en) * | 2002-08-23 | 2010-02-02 | W2 Holdings, Inc. | Thrombospondin fragments and binding agents in the detection, diagnosis and evaluation of cancer |
| AU2003267147A1 (en) * | 2002-09-10 | 2004-04-30 | Placor, Inc. | Method and device for monitoring platelet function |
| US20070243632A1 (en) * | 2003-07-08 | 2007-10-18 | Coller Barry S | Methods for measuring platelet reactivity of patients that have received drug eluting stents |
| ATE536889T1 (de) * | 2003-07-08 | 2011-12-15 | Accumetrics Inc | Kontrollierte thrombozyten-aktivierung zur überwachung der behandlung von adp-antagonisten |
| ES2340378T3 (es) * | 2003-12-16 | 2010-06-02 | Dynabyte Informationssysteme Gmbh | Dispositivo de cartucho para el analisis de sangre. |
| EP2187201B1 (en) | 2003-12-16 | 2012-02-15 | Dynabyte Informationssysteme GmbH | Cartridge device for blood analysis |
| US7439069B2 (en) * | 2004-02-27 | 2008-10-21 | Nippoldt Douglas D | Blood coagulation test cartridge, system, and method |
| US7422905B2 (en) * | 2004-02-27 | 2008-09-09 | Medtronic, Inc. | Blood coagulation test cartridge, system, and method |
| US7399637B2 (en) * | 2004-04-19 | 2008-07-15 | Medtronic, Inc. | Blood coagulation test cartridge, system, and method |
| CA2623142C (en) * | 2004-09-22 | 2016-01-19 | The Regents Of The University Of Colorado, A Body Corporate | Methods for a global assay of coagulation and fibrinolysis |
| EP1875232A2 (en) * | 2005-04-25 | 2008-01-09 | PlaCor, Inc. | Methods and devices for monitoring platelet function |
| US7595169B2 (en) * | 2005-04-27 | 2009-09-29 | Accumetrics, Inc. | Method for determining percent platelet aggregation |
| US7205115B2 (en) * | 2005-04-28 | 2007-04-17 | Accumetrics, Inc. | Method and system for stabilization of arachidonic acid for use in platelet function assay |
| US7932021B2 (en) * | 2005-07-28 | 2011-04-26 | American Diagnostica, Inc. | Lupus anticoagulant testing |
| US20080081379A1 (en) * | 2006-07-13 | 2008-04-03 | Sigler Gerald F | Homogeneous double receptor agglutination assay for immunosuppressant drugs |
| US20100099130A1 (en) * | 2006-10-25 | 2010-04-22 | Placor Inc. | Methods and devices for monitoring platelet function |
| US8197420B2 (en) | 2006-12-18 | 2012-06-12 | Magnolia Medical Technologies, Inc. | Systems and methods for parenterally procuring bodily-fluid samples with reduced contamination |
| EP2153235B1 (en) * | 2007-05-03 | 2012-05-16 | Accumetrics, Inc. | Methods of measuring inhibition of platelet aggregation by thrombin receptor antagonists |
| JP4853666B2 (ja) * | 2007-05-30 | 2012-01-11 | Ｊｓｒ株式会社 | 標的物質の検出方法、混合粒子、および標的物質の検出試薬 |
| US8448499B2 (en) | 2008-12-23 | 2013-05-28 | C A Casyso Ag | Cartridge device for a measuring system for measuring viscoelastic characteristics of a sample liquid, a corresponding measuring system, and a corresponding method |
| US20110165595A1 (en) * | 2009-07-13 | 2011-07-07 | Catanzaro Brian E | Apparatus and methods for processing a whole blood sample |
| US8535241B2 (en) | 2011-10-13 | 2013-09-17 | Magnolia Medical Technologies, Inc. | Fluid diversion mechanism for bodily-fluid sampling |
| US8864684B2 (en) | 2011-10-13 | 2014-10-21 | Magnolia Medical Technologies, Inc. | Fluid diversion mechanism for bodily-fluid sampling |
| US9022951B2 (en) | 2012-05-30 | 2015-05-05 | Magnolia Medical Technologies, Inc. | Fluid diversion mechanism for bodily-fluid sampling |
| US9060724B2 (en) | 2012-05-30 | 2015-06-23 | Magnolia Medical Technologies, Inc. | Fluid diversion mechanism for bodily-fluid sampling |
| WO2014022275A1 (en) | 2012-08-01 | 2014-02-06 | Magnolia Medical Technologies, Inc. | Fluid diversion mechanism for bodily-fluid sampling |
| EP3906952A1 (en) | 2012-10-11 | 2021-11-10 | Magnolia Medical Technologies, Inc. | Systems and methods for delivering a fluid to a patient with reduced contamination |
| EP3498168B1 (en) | 2012-11-30 | 2021-01-20 | Magnolia Medical Technologies, Inc. | Syringe based fluid diversion mechanism for bodily-fluid sampling |
| US10772548B2 (en) | 2012-12-04 | 2020-09-15 | Magnolia Medical Technologies, Inc. | Sterile bodily-fluid collection device and methods |
| CA2932536C (en) | 2012-12-04 | 2023-02-28 | Magnolia Medical Technologies, Inc. | Sterile bodily-fluid collection device and methods |
| JP6437515B2 (ja) | 2013-03-12 | 2018-12-12 | マグノリア メディカル テクノロジーズ，インコーポレイテッド | 針の内腔を選択的に閉塞するための方法及び装置 |
| US9360433B1 (en) | 2013-05-21 | 2016-06-07 | Indevr, Inc. | Detection of agglutination by optical density measurement |
| US10123783B2 (en) | 2014-03-03 | 2018-11-13 | Magnolia Medical Technologies, Inc. | Apparatus and methods for disinfection of a specimen container |
| FR3019900B1 (fr) * | 2014-04-09 | 2017-12-22 | Bio-Rad Innovations | Utilisation de particules absorbantes pour ameliorer la detection du signal dans un procede d'analyse |
| US10539579B2 (en) | 2014-09-29 | 2020-01-21 | C A Casyso Gmbh | Blood testing system and method |
| US10816559B2 (en) | 2014-09-29 | 2020-10-27 | Ca Casyso Ag | Blood testing system and method |
| EP3769681B1 (en) | 2015-06-12 | 2022-03-02 | Magnolia Medical Technologies, Inc. | Bodily-fluid sampling and transfer device |
| EP3733067B1 (en) | 2015-09-03 | 2023-06-14 | Magnolia Medical Technologies, Inc. | System for maintaining sterility of a specimen container |
| JP7121756B2 (ja) * | 2017-02-10 | 2022-08-18 | シー２エヌ ダイアグノスティクス リミテッド ライアビリティ カンパニー | 生物流体中の生体分子の濃度を測定するための方法 |
| EP4249118B1 (en) | 2017-06-09 | 2024-12-11 | Magnolia Medical Technologies, Inc. | Fluid control devices |
| JP7204742B2 (ja) | 2017-09-12 | 2023-01-16 | マグノリア メディカル テクノロジーズ，インコーポレイテッド | 流体制御デバイス及び流体制御デバイスを使用する方法 |
| CN111771054B (zh) | 2017-12-07 | 2022-09-23 | 木兰医药技术股份有限公司 | 流体控制装置及其使用方法 |
| US11786155B2 (en) | 2019-02-08 | 2023-10-17 | Magnolia Medical Technologies, Inc. | Devices and methods for bodily fluid collection and distribution |
| EP3938108B1 (en) | 2019-03-11 | 2023-08-02 | Magnolia Medical Technologies, Inc. | Fluid control devices |
| US12543980B2 (en) | 2021-06-21 | 2026-02-10 | Instrumentation Laboratory Company | Determining a platelet aggregation value |
| CN114935488A (zh) * | 2022-03-23 | 2022-08-23 | 哈尔滨医科大学附属第一医院 | 涡旋混匀法纠正edta依赖性假性血小板减少的方法 |
| CN116625777B (zh) * | 2023-07-21 | 2023-10-13 | 山东新华医疗器械股份有限公司 | 低水平冻干态糖化血红蛋白质控品及其制备方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS54108693A (en) * | 1978-02-14 | 1979-08-25 | Mitsubishi Chem Ind | Method and device for optically measuring antigennantibody reaction |
| US4879219A (en) * | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
| US4973669A (en) * | 1980-09-19 | 1990-11-27 | Massachusetts General Hospital | Monoclonal IgM antibody with specificity against hepatitis B surface antigen |
| US4793180A (en) * | 1981-10-14 | 1988-12-27 | Agm Cargo-Ties, Inc. | Delayed action irreversible humidity indicator |
| US4760030A (en) * | 1984-09-10 | 1988-07-26 | Syntex (U.S.A.) Inc. | Quantitative opaque particle agglutination assay |
| US5004923A (en) * | 1985-08-05 | 1991-04-02 | Biotrack, Inc. | Capillary flow device |
| US5110727A (en) * | 1987-04-03 | 1992-05-05 | Cardiovascular Diagnostics, Inc. | Method for performing coagulation assays accurately, rapidly and simply, using dry chemical reagents and paramagnetic particles |
| US5114842A (en) * | 1987-07-08 | 1992-05-19 | The Scripps Research Institute | Peptides and antibodies that inhibit platelet adhesion |
| US5529901A (en) * | 1987-11-19 | 1996-06-25 | Staat Der Nederlanden | Method for determining the presence or amount of analyte using a stable colloidal carbon sol |
| US5252459A (en) * | 1988-09-23 | 1993-10-12 | Abbott Laboratories | Indicator reagents, diagnostic assays and test kits employing organic polymer latex particles |
| JPH03123861A (ja) * | 1989-10-06 | 1991-05-27 | Mitsubishi Kasei Corp | ハプテンの免疫化学的測定法 |
| US5252496A (en) * | 1989-12-18 | 1993-10-12 | Princeton Biomeditech Corporation | Carbon black immunochemical label |
| US5246832A (en) * | 1990-06-20 | 1993-09-21 | University Of Massachusetts Medical Center | Platelet analysis in whole blood |
| US5427913A (en) * | 1992-12-03 | 1995-06-27 | Alberta Cancer Board | Methods for determining platelet function |
| US5455228A (en) * | 1993-07-02 | 1995-10-03 | The Research Foundation Of State University Of New York | Peptidase resistant thrombin receptor peptide ligand |
| US6238931B1 (en) * | 1993-09-24 | 2001-05-29 | Biosite Diagnostics, Inc. | Fluorescence energy transfer in particles |
| US5763199A (en) * | 1994-09-29 | 1998-06-09 | Mount Sinai School Of Medicine Of The City University Of New York | Platelet blockade assay |
| JP3249919B2 (ja) * | 1996-07-30 | 2002-01-28 | 株式会社堀場製作所 | 免疫測定方法 |
| US6016712A (en) * | 1997-09-18 | 2000-01-25 | Accumetrics | Device for receiving and processing a sample |
-
1997
- 1997-03-20 US US08/820,999 patent/US5922551A/en not_active Expired - Lifetime
-
1998
- 1998-03-20 WO PCT/US1998/006044 patent/WO1998041868A1/en not_active Ceased
- 1998-03-20 DE DE69841387T patent/DE69841387D1/de not_active Expired - Lifetime
- 1998-03-20 CA CA002284559A patent/CA2284559C/en not_active Expired - Lifetime
- 1998-03-20 AT AT98913184T patent/ATE452341T1/de not_active IP Right Cessation
- 1998-03-20 ES ES98913184T patent/ES2336286T3/es not_active Expired - Lifetime
- 1998-03-20 AU AU67796/98A patent/AU6779698A/en not_active Abandoned
- 1998-03-20 EP EP98913184A patent/EP1012604B1/en not_active Expired - Lifetime
- 1998-03-20 JP JP54086998A patent/JP3881036B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE69841387D1 (de) | 2010-01-28 |
| EP1012604A1 (en) | 2000-06-28 |
| JP2002511925A (ja) | 2002-04-16 |
| AU6779698A (en) | 1998-10-12 |
| EP1012604B1 (en) | 2009-12-16 |
| JP3881036B2 (ja) | 2007-02-14 |
| ATE452341T1 (de) | 2010-01-15 |
| US5922551A (en) | 1999-07-13 |
| CA2284559C (en) | 2009-05-12 |
| WO1998041868A1 (en) | 1998-09-24 |
| CA2284559A1 (en) | 1998-09-24 |
| EP1012604A4 (en) | 2002-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2336286T3 (es) | Ensayos aglutrimetricos en sangre. | |
| EP1034429B1 (en) | Device for receiving and processing a sample | |
| US8574828B2 (en) | Controlled platelet activation to monitor therapy of ADP antagonists | |
| US5759774A (en) | Method of detecting circulating antibody types using dried or lyophilized cells | |
| JP5514101B2 (ja) | トロンビンレセプターアンタゴニストによる血小板凝集阻害を測定する方法 | |
| CA2075928A1 (en) | Method of detecting circulating antibody types using dried or lyophilized cells or cell-like material | |
| US7205115B2 (en) | Method and system for stabilization of arachidonic acid for use in platelet function assay | |
| WO2000025140A1 (en) | Method for determining platelet count | |
| US20010046685A1 (en) | Control for methods for determining platelet count and platelet function | |
| Stroncek et al. | Drug‐induced hemolysis: Cefotetan‐dependent hemolytic anemia mimicking an acute intravascular immune transfusion reaction | |
| EP1313810A2 (en) | The use of a multiple dye system to enhance the spectral properties of dyed microparticles in an immunoassay | |
| ES2372760T3 (es) | Procedimiento y sistema para la estabilización del ácido araquidónico para su uso en un ensayo de función de plaquetas. | |
| JP2001330614A (ja) | 生物活性を付与した固相およびその製造方法 | |
| US20260009805A1 (en) | Platelet Count Assay | |
| BR112017019236B1 (pt) | Kit, e, método para detectar a presença de anticorpos de sífilis em uma amostra |